OBJECTIVE: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. METHOD:A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. RESULTS: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). CONCLUSIONS: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.
RCT Entities:
OBJECTIVE: The authors sought to assess the relationship between candidate genes and two clinical outcomes, namely, symptomatic improvement and the occurrence of suicidal events, in a sample of treatment-resistant depressed adolescents. METHOD: A subsample of depressed adolescents participating in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) trial, 155 of whom were of European origin, were genotyped with respect to 21 polymorphisms on 12 genes that have a reported association with depression, treatment response, or suicidal events. Participants had not responded to a previous adequate trial with an antidepressant and were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therapy (CBT). Single-nucleotide polymorphism (SNP) analyses were conducted using PLINK with permutation procedures. RESULTS: No relationship was observed between any polymorphism and response to treatment. The FKBP5 (which codes for a protein causing subsensitivity of the glucocorticoid receptor) rs1360780TT and rs3800373GG genotypes were associated with suicidal events (N=18), even after controlling for treatment effects and relevant covariates. These two SNPs were in significant linkage disequilibrium (r=0.91). CONCLUSIONS: The FKBP5 genotypes associated with suicidal events in this study have been reported by others to cause the greatest degree of glucocorticoid receptor subsensitivity. These results are consistent with those of other studies linking alterations in the hypothalamic-pituitary-adrenal axis with suicidal behavior. The small number of events and lack of a placebo condition make these results preliminary. Replication with a larger sample and a placebo condition is needed to assess whether these events are related to treatment.
Authors: K C Koenen; G Saxe; S Purcell; J W Smoller; D Bartholomew; A Miller; E Hall; J Kaplow; M Bosquet; S Moulton; C Baldwin Journal: Mol Psychiatry Date: 2005-12 Impact factor: 15.992
Authors: Matthew K Nock; Thomas E Joiner; Kathryn H Gordon; Elizabeth Lloyd-Richardson; Mitchell J Prinstein Journal: Psychiatry Res Date: 2006-08-02 Impact factor: 3.222
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Francis J McMahon; Silvia Buervenich; Dennis Charney; Robert Lipsky; A John Rush; Alexander F Wilson; Alexa J M Sorant; George J Papanicolaou; Gonzalo Laje; Maurizio Fava; Madhukar H Trivedi; Stephen R Wisniewski; Husseini Manji Journal: Am J Hum Genet Date: 2006-03-20 Impact factor: 11.025
Authors: Elisabeth B Binder; Daria Salyakina; Peter Lichtner; Gabriele M Wochnik; Marcus Ising; Benno Pütz; Sergi Papiol; Shaun Seaman; Susanne Lucae; Martin A Kohli; Thomas Nickel; Heike E Künzel; Brigitte Fuchs; Matthias Majer; Andrea Pfennig; Nikola Kern; Jürgen Brunner; Sieglinde Modell; Thomas Baghai; Tobias Deiml; Peter Zill; Brigitta Bondy; Rainer Rupprecht; Thomas Messer; Oliver Köhnlein; Heike Dabitz; Tanja Brückl; Nina Müller; Hildegard Pfister; Roselind Lieb; Jakob C Mueller; Elin Lõhmussaar; Tim M Strom; Thomas Bettecken; Thomas Meitinger; Manfred Uhr; Theo Rein; Florian Holsboer; Bertram Muller-Myhsok Journal: Nat Genet Date: 2004-11-21 Impact factor: 38.330
Authors: Julia Kirchheiner; Rainer Lorch; Elena Lebedeva; Angela Seeringer; Ivar Roots; Johanna Sasse; Jürgen Brockmöller Journal: Pharmacogenomics Date: 2008-07 Impact factor: 2.533
Authors: Chase H Bourke; Madiha Q Raees; Sanjana Malviya; Cory A Bradburn; Elisabeth B Binder; Gretchen N Neigh Journal: Psychoneuroendocrinology Date: 2012-05-29 Impact factor: 4.905
Authors: Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox Journal: Trends Endocrinol Metab Date: 2011-08-31 Impact factor: 12.015
Authors: Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang Journal: Pharmacogenet Genomics Date: 2013-03 Impact factor: 2.089